9QFV | pdb_00009qfv

Human Tryptase beta-2 (hTPSB2)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.06 Å
  • R-Value Free: 
    0.219 (Depositor), 0.227 (DCC) 
  • R-Value Work: 
    0.188 (Depositor), 0.195 (DCC) 
  • R-Value Observed: 
    0.188 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9QFV

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

Integrating Surface Plasmon Resonance and Docking Analysis for Mechanistic Insights of Tryptase Inhibitors.

Porta, A.Manelfi, C.Talarico, C.Beccari, A.R.Brindisi, M.Summa, V.Iaconis, D.Gobbi, M.Beeg, M.

(2025) Molecules 30

  • DOI: https://doi.org/10.3390/molecules30061338
  • Primary Citation Related Structures: 
    9QFU, 9QFV

  • PubMed Abstract: 

    Tryptase is a tetrameric serine protease and a key component of mast cell granules. Here, we explored an integrated approach to characterize tryptase ligands, combining novel experimental binding studies using Surface Plasmon Resonance, with in silico analysis through the Exscalate platform. For this, we focused on three inhibitors previously reported in the literature, including a bivalent inhibitor and its corresponding monovalent compound. All three ligands showed concentration-dependent binding to immobilized human tryptase with the bivalent inhibitor showing the highest affinity. Furthermore, Rmax values were similar, indicating that the compounds occupy all four binding pockets of the tryptase tetramer. This hypothesis was supported by in silico computational analysis that revealed the binding mode of the monovalent ligand, one in each monomer pocket, compared with crystal structure of the bivalent one, which simultaneously occupies two binding pockets. Additionally, we solved the 2.06 Å X-ray crystal structures of human Tryptase beta-2 (hTPSB2), in both its apo form and in complex with compound # 1 , experimentally confirming the binding mode and the key molecular interactions predicted by docking studies for this compound. This integrated approach offers a robust framework for elucidating both the strength and mode of interaction of potential tryptase inhibitors.


  • Organizational Affiliation
    • Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milano, Italy.

Macromolecule Content 

  • Total Structure Weight: 113.4 kDa 
  • Atom Count: 8,560 
  • Modeled Residue Count: 976 
  • Deposited Residue Count: 980 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Tryptase beta-2
A, B, C, D
245Homo sapiensMutation(s): 0 
EC: 3.4.21.59
UniProt & NIH Common Fund Data Resources
Find proteins for P20231 (Homo sapiens)
Explore P20231 
Go to UniProtKB:  P20231
PHAROS:  P20231
GTEx:  ENSG00000197253 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP20231
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 6 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
1PE
(Subject of Investigation/LOI)

Query on 1PE



Download:Ideal Coordinates CCD File
JA [auth D],
Q [auth B]
PENTAETHYLENE GLYCOL
C10 H22 O6
JLFNLZLINWHATN-UHFFFAOYSA-N
MES
(Subject of Investigation/LOI)

Query on MES



Download:Ideal Coordinates CCD File
J [auth A],
KA [auth D],
U [auth B],
X [auth C]
2-(N-MORPHOLINO)-ETHANESULFONIC ACID
C6 H13 N O4 S
SXGZJKUKBWWHRA-UHFFFAOYSA-N
SO4
(Subject of Investigation/LOI)

Query on SO4



Download:Ideal Coordinates CCD File
CA [auth C]
G [auth A]
GA [auth D]
HA [auth D]
N [auth A]
CA [auth C],
G [auth A],
GA [auth D],
HA [auth D],
N [auth A],
R [auth B],
S [auth B],
Z [auth C]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
GOL
(Subject of Investigation/LOI)

Query on GOL



Download:Ideal Coordinates CCD File
AA [auth C],
I [auth A],
MA [auth D],
W [auth B]
GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
EDO
(Subject of Investigation/LOI)

Query on EDO



Download:Ideal Coordinates CCD File
BA [auth C]
DA [auth C]
F [auth A]
FA [auth D]
H [auth A]
BA [auth C],
DA [auth C],
F [auth A],
FA [auth D],
H [auth A],
IA [auth D],
K [auth A],
L [auth A],
LA [auth D],
M [auth A],
P [auth B],
T [auth B],
V [auth B]
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
ACT
(Subject of Investigation/LOI)

Query on ACT



Download:Ideal Coordinates CCD File
E [auth A],
EA [auth D],
O [auth B],
Y [auth C]
ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.06 Å
  • R-Value Free:  0.219 (Depositor), 0.227 (DCC) 
  • R-Value Work:  0.188 (Depositor), 0.195 (DCC) 
  • R-Value Observed: 0.188 (Depositor) 
Space Group: P 31
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 78.634α = 90
b = 78.634β = 90
c = 165.051γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
autoPROCdata reduction
autoPROCdata scaling
REFMACphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2025-03-26
    Type: Initial release
  • Version 1.1: 2025-04-09
    Changes: Database references